Seeking Alpha

MDinvestor

MDinvestor
Send Message
View as an RSS Feed
View MDinvestor's Comments BY TICKER:
Latest  |  Highest rated
  • Ampio's Promising Pipeline Could Send Company Higher [View article]
    Indie... You deserve a pat on the back. A year later the stock is up significantly. And you're right... It's just the beginning. Expect another double very soon. Possibly into 20s even in a very short time.
    Oct 19, 2013. 01:55 AM | Likes Like |Link to Comment
  • Ampio Momentum Continues After Positive Initial Phase III Data [View article]
    Ditto
    Aug 27, 2013. 12:06 AM | Likes Like |Link to Comment
  • Ohr Pharmaceutical: Eye Drop Treatment For Wet AMD Could Sideline Eylea Momentum [View article]
    A better bet with a much shorter time frame would be AMPE with Phase III interim results in Q4 this year, full Phase III results in Q1 and actual approval possible in 2014. It was the cover story in the prestigious Retina Today magazine. It is in pill form (frankly even easier than an eye drop) and goes tot he repairing the cause of DME and not just treating the symptom.
    Jul 19, 2013. 02:59 PM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way [View article]
    Its not worth the time and effort to go through everything that is absurd about this "article" but let me just start at the top.

    I don't know anything about Isolagen (not that what happened to Isolagen after Macaluso left, and in which he was not implicated, have anything to do with AMPE) but the article first makes the tie-in to Isolagen by stating "Well a number of those same executives were the original founders of Ampio Pharmaceuticals." WRONG!! - LIE!!

    Ampio was "founded" through a name change from Chay Enterprises (a public shell company) "acquired" through a reverse merger with DMI LifeSciences. DMI Life Sciences was a spin-off from DMI BioSciences. It was NOT "founded" by a number of Isolagen executives. Macaluso made a significant cash investment into the company for his shares. The founders of DMI BioSciences where the founders of Ampio, and had been with DMI for 20 years.

    Oh, heck, while I'm at it, I'll hit the next paragraph a bit: "Of course Ampio had no assets." WRONG!! - LIE!! Ampio had significant assets primarily consisting of technology from DMI (a company that was founded by David Bar-Or, and has been developing technology since the early 1990s).

    Then we have this gem: "Management was savvy enough, before this idea got off the ground, to issue themselves 7.35 million shares of stock for a penny a share in April of 2009." What? What idea is that specifically? The idea of forming a spin-off company from that which you invested in and part of the deal is issuing shares in the spin-off for a nominal amount? Its done all the time. The idea was to build a company and commercialize technology that's been developed over the past 20 years. Good idea, if you ask me. Yes, Macaluso had a lot more shares before - I'll have to go dig it all out and check, but I seem to recall he gave a bunch back to induce DMI (Ampio's former "parent") to transfer the balance of its technology to Ampio.

    I could go on - and on - and take days disproving almost every falsehood and innuendo of improper or "scam-like" behavior. The article is all BS and nothing but a desperate attempt to negatively effect the share price so the short investors can cover not only their shares, but their butts.
    Jun 7, 2013. 11:45 AM | 3 Likes Like |Link to Comment
  • Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way [View article]
    The only thing 100% true in this article is that the author is SHORT. It explains a lot.... the half truths, innuendo, guilt by association, convenient manipulation, etc. etc. Its BS. A lot time was out in to putting this together... he must really scared and/or really hurting.
    Jun 6, 2013. 06:15 PM | 3 Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    Adam F is a well known for working for hedge funds that short stocks. With respect to Ampio he has been bashing the company for years and has been proven wrong at every turn. IE: Ampio shares will tumble due to management lock-ups ending and management will dump all their stock as soon as they can ... Wrong. Lock up has been long gone and no insider sales.

    His dumping on Optina is typical. instead take a look at an objective analysis from "Retina Today" magazine. No point in telling you, though - it doesn't help your short position. Must be feeling the squeeze about now.
    May 30, 2013. 07:34 PM | 1 Like Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    Keep laughing bio-bobby. As stated above, you need to have an understanding of the drug, its genesis, its purpose in the body, and its mechanism of action in order to have any kind of understanding of its potential.

    He who laughs last ..... you know.
    May 30, 2013. 05:26 PM | Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    Here, as well as in the case of Ampion (below), you have an obvious lack of understanding of the science and mechanism of action with Optina. Optina uses a dosage of Danazol that is about 5% of the common dosage - that's 1/20th. Try to slice off 1/20th of a pill! Not to mention being able to get someone to prescribe it for off-label use. Then add to that the fact that too much or too little (based on your BMI) could have the OPPOSITE impact. Not a very good idea to try to save a few dollars - if it was even practically possible.
    May 30, 2013. 05:22 PM | Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    In order to gain proper perspective you need understand the cyclic dipepetide (Ampion), how and why it is created in the body, and its mechanism of action, potential uses, and incredible markets.
    May 30, 2013. 05:17 PM | Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    Under a managed care program (getting more and more prevalent), the "lucrative business" of Lucentis and Eyelea becomes just the opposite... adding more fuel to the advantages of Optina. More and more insurers and government programs are tying sound medicine to sound economics, resulting in greater difficulty in justifying an expensive treatment when a less costly one is available.
    May 30, 2013. 05:13 PM | Likes Like |Link to Comment
  • Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players [View article]
    I agree 100%. Optina will be a godsend to those suffering from DME.

    From a stock perspective, the risk profile for REGN has increased dramatically. AMPE appears to potentially be the next biopharma explosion story. It won't be a surprise to some, but many others will be blindsided by this little unknown company who suddenly will become a significant player.
    Apr 4, 2013. 09:42 AM | 1 Like Like |Link to Comment
  • Retail Speculators Getting Amped On Ampio Pharmaceuticals [View article]
    Adam... like The Banker, you have no clue.... DMI (originally Diagnostic Markers, Inc.) was formed in 1991. It changed its name to DMI BioSciences. DMI Bio then spun off DMI LifeSciences with some of its technologies. DMI Life then did the reverse merger with Chay and became Ampio. Ampio then acquired DMI Bio. Hello??? Get the picture here? The company (in its various iterations) has been around for 20 years. Much of the management has been involved for decades and very often worked for no cash, showing pure and remarkable dedication to the science they were pursuing. Rachael and David Bar-Or amongst them.
    Dec 14, 2011. 06:23 PM | Likes Like |Link to Comment
  • Retail Speculators Getting Amped On Ampio Pharmaceuticals [View article]
    I have personally met, spoken with and grilled the CSO and his son. The son's brilliance is only matched by his father (or vice versa) and both are mind-boggling and a couple of the brightest people I have ever encountered. Either way the company is extremely fortunate to have them both.
    Dec 14, 2011. 03:44 PM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: It's The Pipeline That Talks [View article]
    If you actually look at the 13G filing, it dates to the acquisition of shares (1,542,707) by Genesis on March 23, 2011. Per the S-1A filed by the company, those shares have never been subject to any lock-up agreement whatsoever, and thus there is nothing magical about January 1st and those shares.

    Nice try, though.
    Dec 14, 2011. 11:27 AM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: Anywhere But Straight Out Of Isolagen's Playbook [View article]
    If you actually look at the 13G filing, it dates to the acquisition of shares (1,542,707) by Genesis on March 23, 2011. Per the S-1A filed by the company, those shares have never been subject to any lock-up agreement whatsoever, and thus there is nothing magical about January 1st and those shares.
    Dec 14, 2011. 11:25 AM | 2 Likes Like |Link to Comment
COMMENTS STATS
16 Comments
11 Likes